default author photo

Serena Koenig

Harvard University - Harvard Medical School

SCHOLARLY PAPERS

2

DOWNLOADS

239

TOTAL CITATIONS

0

Scholarly Papers (2)

1.

Bictegravir/Emtricitabine/Tenofovir Alafenamide Versus Ritonavir-Boosted Protease Inhibitor-Based Antiretroviral Therapy in Persons with HIV and Viral Suppression on Second-Line Therapy: An Open-Label Randomized Non-Inferiority Trial

Number of pages: 27 Posted: 02 Jan 2025
Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Harvard University - Department of Global Health and Social Medicine, Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Analysis Group, Inc., Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Analysis Group, Inc., Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), National Institute of Respiratory Diseases ”Ismael Cosío Villegas” - Centre for Research in Infectious Diseases, National Institute of Respiratory Diseases, Analysis Group, Inc., Gilead Sciences, Inc., Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Cornell University, Analysis Group, Inc., Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Gilead Sciences, Inc., Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Harvard University - Division of Infectious Disease and Harvard University - Harvard Medical School
Downloads 147 (505,974)

Abstract:

Loading...

HIV, INSTI, bictegravir, protease inhibitor, tenofovir alafenamide, tenofovir disoproxil fumarate

2.

Temporal Trends in Tuberculosis and the Time from Enrollment in Care to Antiretroviral Therapy Initiation Among People Living with HIV in Latin America

Number of pages: 23 Posted: 10 Feb 2025
Vanderbilt University Medical Center - Department of Biostatistics, Vanderbilt University - Medical Center, Vanderbilt University - Medical Center, Instituto de Investigaciones Clínicas Zárate, Oswaldo Cruz Foundation (FIOCRUZ) - Instituto Nacional de Infectologia Evandro Chagas (INIEC), University of Chile - Faculty of Medicine, Hospital Escuela, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Universidad Peruana Cayetano Heredia, Vanderbilt University - Medical Center, Vanderbilt University - Medical Center, Les Centres Haitian Group for the Study of Kaposi's Sarcoma and Opportunistic Infections (GHESKIO), Vanderbilt University - Division of Infectious Diseases and Harvard University - Harvard Medical School
Downloads 92 (730,864)

Abstract:

Loading...

HIV, Tuberculosis, Antiretroviral Therapy, Same-Day Treatment, Latin America, Caribbean